An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity. (25th April 2018)

• Record Type: Journal Article
• Authors: Ramachandran, Sulabha; Parks, Daniel; Kurtinecz, Milena; Roth, David A; Alfonso-Cristancho, Rafael
• Is Part Of: Journal of comparative effectiveness research. Volume 7:Number 6(2018)
• Page Start: 581
• Page End: 593
• Publication Date: 2018-04-25
• Subjects: belimumab -- high disease activity -- indirect treatment comparison -- lupus -- systemic lupus erythematosus; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer-2017-0085
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: To compare the efficacy of intravenous (IV) and subcutaneous (SC) belimumab plus standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus and high disease activity (HDA).Patients & methods: An indirect treatment comparison using patient-level data of patients with HDA from three belimumab IV Phase III randomized controlled trials (BLISS-52 [BEL110751]; BLISS-76 [BEL110752]; Northeast Asia study [BEL113750]) and one belimumab SC randomized controlled trial (BLISS-SC [BEL112341]).Results: Similar efficacy results were identified between the belimumab formulations and greater improvements in efficacy endpoints were observed for both formulations compared with placebo.Conclusion: This indirect treatment comparison provides further evidence of the efficacy of belimumab IV and SC in patients with systemic lupus erythematosus and HDA, compared with standard therapy.